Evaluation of $^{18}$F-nifene binding to $\alpha4\beta2$ nicotinic receptors in the rat brain using microPET imaging

Ritu Kant, Cristian C Constantinescu, Puja Parekh, Suresh K Pandey, Min-Liang Pan, Balu Easwaramoorthy and Jogeshwar Mukherjee*

Abstract

MicroPET imaging studies using $^{18}$F-nifene, a new positron emission tomography (PET) radiotracer for nicotinic acetylcholinergic receptors (nAChR) $\alpha4\beta2$ receptors in rats, have been carried out. Rats were imaged for 90 min after intravenous injection of $^{18}$F-nifene (0.8 to 1 mCi), and binding potential (BPND) was measured. $^{18}$F-Nifene binding to thalamic and extrathalamic brain regions was consistent with the $\alpha4\beta2$ nAChR distribution in the rat brain. Using the cerebellum as a reference, the values for the thalamus varied less than 5% (BPND = 1.30, n = 3), confirming reproducibility of $^{18}$F-nifene binding. $^{18}$F-Nifene microPET imaging was also used to evaluate effects of nicotine in a group of Sprague-Dawley rats under isoflurane anesthesia. Nicotine challenge postadministration of $^{18}$F-nifene demonstrated reversibility of $^{18}$F-nifene binding in vivo. For $\alpha4\beta2$ nAChR receptor occupancy (nAChROCC), various doses of nicotine (0, 0.02, 0.1, 0.25, and 0.50 mg/kg nicotine free base) 15 min prior to $^{18}$F-nifene were administered. Low-dose nicotine (0.02 mg) reached > 80% nAChROCC while at higher doses (0.25 mg) > 90% nAChROCC was measured. The small amount of $^{18}$F-nifene binding with reference to the cerebellum affects an accurate evaluation of nAChROCC. Efforts are underway to identify alternate reference regions for $^{18}$F-nifene microPET studies in rodents.

Background

Nicotinic $\alpha4\beta2$ receptors play an important role in many CNS disorders such as Alzheimer’s disease, Parkinson’s disease, Schizophrenia, mood disorders, and nicotine dependence. Much work is being done on radiotracer compounds with high binding affinity as well as faster kinetics which can be used as an aid to visualize the nicotinic receptors and their involvement in neurological disorders [1]. Both 5-$^{123}$I-iodo-A-85380 and 2-$^{18}$F-fluoro-A-85380 have a high affinity for the $\alpha4\beta2$ receptors with scan times exceeding several hours. In order to reduce the scan time, emphasis was placed on developing a tracer with faster kinetics. We have developed $^{18}$F-nifene (2-$^{18}$F-fluoro-3-[(S)-3-pyrrolinyl]methoxy)pyridine; Figure 1), a nicotinic $\alpha4\beta2$ receptor agonist which is suitable for positron emission tomography (PET) imaging ($K_i = 0.50$ nM [2,3]). Imaging times in nonhuman primates with $^{18}$F-nifene [2] were reduced significantly compared to $^{18}$F-fluro-A-85380 [4].

Nicotine has a high affinity for $\alpha4\beta2$ nicotinic acetylcholinergic receptors (nAChR) receptors ($K_i = 1.68$ nM, [3]). Cigarette smoking and nicotine (a major component of tobacco) have been shown to have a direct and significant occupancy of $\alpha4\beta2$ nAChR receptors [5-7]. Studies have also shown an increase in $\alpha4\beta2$ receptor density binding sites in rat and mice brains upon exposure to nicotine [8-10]. Chronic tobacco smoking increases the number of high affinity nAChRs in various brain areas [11]. Human postmortem data have shown the presence of $\alpha4\beta2$ nAChR receptors in the subiculum, which are upregulated in smokers [10]. Human imaging studies, using SPECT imaging agent 5-$^{123}$I-iodo-A-85380 and PET imaging agent 2-$^{18}$F-fluoro-A-85380, have also identified an increase in receptor density among smokers versus nonsmokers, suggesting 2-$^{18}$F-fluoro-A-85380 to be a reliable PET method for further tobacco studies [12,13]. As reported recently, nicotine from typical cigarette smoking by daily smokers is likely to occupy a majority of $\alpha4\beta2$ receptors and lend them to a desensitized state [5]. Thus, noninvasive imaging is playing a major role in understanding nicotine dependency [14,15].
The focus in this work is on in vivo evaluation of 18F-nifene binding to α4β2 nicotinic receptors in rodent brain regions using microPET. In an effort to establish 18F-nifene microPET studies in the rat model, our objectives were the following: (1) evaluate in vivo 18F-nifene in the normal rat model using microPET and confirm by ex vivo microPET and autoradiography, (2) carry out test-retest microPET studies in the rat model in order to evaluate reproducibility of 18F-nifene microPET binding, and (3) measure changes in 18F-nifene binding in the rat model using microPET at different doses of nicotine. These findings will assist in our eventual goal to evaluate the role of α4β2 nAChR in nicotine dependency using the rodent model.

**Methods**

**General methods**

All chemicals and solvents were purchased from Aldrich Chemical (Aldrich Chemical Company, Wilwaukee, WI, USA) and Fisher Scientific (Fisher Scientific UK Ltd., Leicestershire, UK). Deionized water was acquired from Millipore Milli-Q Water Purification System (Millipore, Billerica, MA, USA). Gilson high-performance liquid chromatography (HPLC) was used for the semipreparative reverse phase column chromatography. Fluorine-18 fluoride was produced via MC-17 cyclotron using oxygen-18-enriched water. Radioactivity was counted using a Capintec dose calibrator while low level counting was done using a well counter. Inveon preclinical Dedicated PET (Siemens’s Inc., Munich, Germany) was used for the microPET studies which has a resolution of 1.45 mm [16]. Both in vivo and ex vivo images of the rat brains were obtained using the Inveon microPET scanner and were analyzed using the Acquisition Sinogram Image Processing (ASIPro, Siemens Medical Solutions USA, Inc., Knoxville, TN, USA) and Pixelwise Modeling Software (PMOD Technologies, Zürich, Switzerland). Slices of the rat brain were prepared at 10 to 40-μm thick using the Leica 1850 cryotome (Leica Instruments, Nussloch, Germany). In vitro- or ex vivo-labeled brain sections were exposed to phosphor films (Perkin Elmer Multisensitive, Medium MS) and were read using the Cyclone Phosphor Imaging System (Packard Instruments, Meriden, CT, USA). An analysis of in vitro or ex vivo autoradiographs was done using the Optiquant Acquisition and Analysis software (Packard Instruments, Meriden, CT, USA). All animal studies have been approved by the Institutional Animal Health Care and Use Committee of the University of California, Irvine.

**Radiolabeling**

A synthesis of 18F-nifene was carried out following reported procedures (Pichika et al. 2006). The automated radiosynthesis of 18F-nifene was carried out in the chemistry processing control unit box. An Alltech C18 column (10 μm, 250 × 10 mm2) was used for reverse phase HPLC purification and specific activity of 18F-nifene was approximately 2,000 Ci/mmol.

**MicroPET 18F-nifene studies**

Male Sprague-Dawley rats were fasted 24 h prior to the time of scan. On the day of the study, rats were anesthetized using 4.0% isoflurane. The rat was then positioned on the scanner bed by placing it on a warm water circulating heating pad, and anesthesia was applied using a nose cone. A transmission scan was subsequently acquired. The preparation of the dose injection was as follows: 0.7-1.0 mCi of 18F-nifene was drawn into a 1-mL syringe with a 25-gauge needle and was diluted with sterile saline to a final volume of 0.3 mL. The dose was injected intravenously into the tail vein of the rat. Isoflurane was reduced and maintained at 2.5% following the injection. The scans were carried out for 90 min and were acquired by the Inveon microPET in full list mode. The list mode data were collected dynamically which were rebinned using a Fourier rebinning algorithm. The images were reconstructed using a two-dimensional Filter Back Projection using a Hanning Filter with a Nyquist cutoff at 0.5, and were corrected for attenuation using the Co-57 attenuation scan data. A calibration was conducted to Becquerel per cubic centimeter units using a germanium-68 phantom which was scanned in the Inveon microPET and was reconstructed under the same parameters as the subjects. Analyses of all data were carried out using the Acquisition Sinogram Image Processing IDL’s virtual machine (ASIPro VM) and Pixelwise Modeling software (PMOD 3.0). The test and retest microPET studies on the same animal were carried out within an interval of approximately 2 weeks.

**Metabolite analysis**

Blood was collected at four different time points (5, 15, 60, and 90 min) after the injection of 18F-nifene. The blood was centrifuged for 5 min at 3,000 g. The plasma was separated and counted. Acetonitrile was added to the blood samples, and the organic layer was spotted on the analytical thin layer chromatography (TLC) plates.
and was developed in 15% methanol in dichloromethane. A sample of the plasma was also collected prior to the injection of $^{18}$F-nifene and was spiked with the tracer and was used as a standard.

Male Sprague-Dawley rats were injected intravenously (IV) with 0.5 mCi of $^{18}$F-nifene in a total volume of 0.3 mL and were sacrificed 40 min after injection. The brain was extracted and dissected into two hemispheres. The sagittal sections of 40-μm thickness were obtained from the left hemisphere using the Leica 1850 cryotome and were exposed to phosphor films overnight. The films were read using the Cyclone Phosphor Imaging System and were analyzed using the Optiquant software. The right hemisphere was homogenized with 1.15% KCl (2 mL), and this homogenized mixture was vortexed with 2% acetic acid in methanol (2 mL). This mixture was centrifuged for 10 min at 10,000 g, and the supernatant was removed for analysis. RadioTLC (9:1, dichloromethane and methanol) was obtained for both $^{18}$F-nifene standard and the brain extract.

Ex vivo microPET

In order to ascertain the brain uptake of $^{18}$F-nifene, after completion of the in vivo microPET scans, the rats were sacrificed and the brain was extracted for ex vivo microPET imaging. The whole brain was placed in a hexagonal polystyrene weighing boat (top edge side length, 4.5 cm; bottom edge side length, 3 cm) and was covered with powdered dry ice. This boat was placed securely on the scanner bed, and a transmission scan was acquired. Subsequently, a 60-min emission scan was acquired by the Inveon microPET scanner in full list mode. The list mode was collected in a single frame, and a reconstruction of the images was similar to the procedure described previously in the section “MicroPET 18F-nifene studies.” The images were analyzed using the ASIPRO VM and PMOD 3.0 software.

Ex vivo autoradiography

The brain after the ex vivo microPET acquisition in the section “Ex vivo microPET” was removed from the dry ice and was rapidly prepared for sectioning. Horizontal sections (40-μm thick) containing brain regions of the thalamus, subiculum, cortex, striatum, hippocampus, and cerebellum were cut using the Leica CM1850 cryotome. The sections were air-dried and exposed to phosphor films overnight. The films were read using the Cyclone Phosphor Imaging System. The regions of interest of the films overnight. The films were read using the Cyclone Phosphor Imaging System and were analyzed using the Optiquant software. Percent occupancy was calculated from: $(\text{Thal}_{\text{cont}} - \text{Thal}_{\text{nic}}/\text{Thal}_{\text{cont}}) \times 100$, where $\text{Thal}_{\text{cont}}$ is the percent injected dose of $^{18}$F-nifene in the brain regions of the control study, and $\text{Thal}_{\text{nic}}$ is the percent injected dose of $^{18}$F-nifene in the brain regions of the nicotine study at 60 min postinjection of $^{18}$F-nifene.

Results

MicroPET $^{18}$F-nifene binding studies

A rapid uptake of $^{18}$F-nifene was observed in the brain with levels of approximately 1% of injected dose per cubic centimeter. Thalamic regions exhibited the highest retention as it has a maximum amount of $\alpha 4\beta 2$ receptors. Significant levels of uptake were observed in the various regions of the cortex while very little binding is present in the cerebellum (Figure 2A,B,C). Time-activity curves of the thalamus, frontal cortex, and cerebellum in Figure 2D show initial rapid uptake in various brain regions followed by greater retention in the thalamus and cortex compared to the cerebellum. A ratio of the uptake for the thalamus and frontal cortex against the reference region cerebellum reached a plateau at approximately 60 min postinjection. The thalamus to
cerebellum ratio was approximately 3.5 and the cortex to cerebellum ratio was 2.3.

**Metabolite analysis**

Following the injection of $^{18}$F-nifene, blood was collected at different time points to measure metabolites in the blood plasma. Figure 3A shows a decrease in the amount of parent as well as metabolites found in the blood plasma during the 90 min. $^{18}$F-Nifene standard was used to compare the tracer found in the blood plasma. Figure 3B represents about 42% of $^{18}$F-nifene remaining in the blood plasma at 90 min (compared to that measured at 5 min pi) while the levels of metabolites were significantly reduced in the blood plasma at 90 min.

Radiochromatograms were attained from running brain extracts and were compared to the peak to the parent compound providing evidence that the primary species within the brain of the rat was $^{18}$F-nifene. After sacrificing the rat, the brain was excised and dissected into the left and right hemispheres. Figure 3C,D shows the sagittal brain slices of the left hemisphere representing the total binding of $^{18}$F-nifene revealing maximal binding in the thalamus followed by extrathalamic regions such as the cortex and subiculum. The cerebellum had the least amount of activity. A thin layer chromatographic analysis of the extract of the homogenized right hemisphere shown in Figure 3F closely correlates with the retention of $^{18}$F-nifene standard (Figure 3D). No other significant metabolite peak was observed in the brain extract.

**Test-retest**

Test and retest studies were investigated in a group of rats (Figure 2). Binding of $^{18}$F-nifene in each region of the brain remained consistent among the studies. Figure 2 represents the time-activity curves for a test-retest study in one animal. The curve seen for the retest study follows the same pattern as the test study. By 60 min into the scan, nonspecific binding is seen to be cleared.
out in both studies and remains at stable levels. The binding potentials for the three rats were calculated and were found to vary between 1.03 and 1.69, but within subject, the test-retest error was approximately 3% (Table 1).

**Ex vivo studies**

*Ex vivo* microPET imaging of the excised brain after 90 min of *in vivo* scans was carried out for another 60 min. Results clearly show binding of $^{18}$F-nifene in the thalamus, cortical regions with little binding in the cerebellum (Figure 4A,B,C). This is consistent with the *in vivo* images shown in Figure 2A,B,C.

![Figure 3 Blood and brain metabolite analysis in rats postadministration of intravenous $^{18}$F-nifene](image)

**Figure 3 Blood and brain metabolite analysis in rats postadministration of intravenous $^{18}$F-nifene** (A) Blood plasma collected at different time points (5, 15, 60, and 90 min) and compared to $^{18}$F-nifene standard on TLC. A polar metabolite is seen, but the predominant radioactive species is $^{18}$F-nifene. (B) Analysis of TLC in (A) indicates 42% of $^{18}$F-nifene (blue) remaining at 90 min with little polar metabolites (red) remaining in the plasma. (C) Ex vivo rat brain was dissected into two hemispheres—the left hemisphere was cut into 40-μm thick sagittal brain sections and were scanned to reveal brain areas. (D) Binding of $^{18}$F-nifene in the thalamus (TH), cortex (COR), and least binding in the cerebellum (CB) was observed. (E) RadioTLC of $^{18}$F-nifene standard with 9:1 CH$_2$Cl$_2$:CH$_3$OH. (F) RadioTLC of brain extracts with 9:1 CH$_2$Cl$_2$:CH$_3$OH showing the presence of $^{18}$F-nifene.

**Table 1 Test-retest $^{18}$F-nifene binding potential in thalamus**

| Rat   | Test | Retest | Mean | %Error |
|-------|------|--------|------|--------|
| 1     | 1.69 | 1.64   | 1.67 | 3.0%   |
| 2     | 1.17 | 1.21   | 1.19 | 3.4%   |
| 3     | 1.06 | 1.03   | 1.05 | 2.9%   |

Error estimates are given as [(Scan1-Scan2)/(Scan1 + Scan2)/2] × 100

*Ex vivo* autoradiographs revealed a significant amount of detail that was not readily apparent in the microPET images. The thalamus exhibited the highest amount of $^{18}$F-nifene binding. The subiculum had a higher amount
of binding in the autoradiographs not readily measurable in the microPET data. The cortex had a significant amount of binding consistent to that observed in the microPET imaging data. The cerebellum had the lowest amount of 18F-nifene binding in the ex vivo autoradiographs. Autoradiographic ratios with respect to the cerebellum in the various brain regions were: thalamus = 4.60, subiculum = 2.39, cortex = 1.83, striatum = 1.46. These ratios are in close agreement to the ratios measured by microPET ex vivo (Table 2).

### Table 2 Measured 18F-nifene ratios of rat brain regions with reference to the cerebellum

| Brain regions | In vivo microPET | Ex vivo microPET | Ex vivo autoradiograph |
|---------------|-----------------|-----------------|------------------------|
| Thalamus      | 3.13 ± 0.29     | 3.92 ± 0.49     | 4.60 ± 0.52            |
| Subiculum     | -               | 2.28 ± 0.24     | 2.39 ± 0.15            |
| Cortex        | 1.98 ± 0.10     | 2.05 ± 0.17     | 1.83 ± 0.19            |
| Striatum      | 1.52 ± 0.39     | 1.77 ± 0.28     | 1.46 ± 0.07            |

Average of four animals with standard deviations; *Ratio measured at 85-90 min postinjection of 18F-nifene; †Ratio measured in the 60-min summed ex vivo scan of the same rats; ‡Ratios measured in sections after the ex vivo scans of the same rats.

### MicroPET studies of nicotine challenges

In the first set of experiments with nicotine, 18F-nifene bound in the thalamus (Figure 5A) was displaced by IV administration of 0.3 mg/kg of nicotine (Figure 5B). The time-activity curve for this competition of nicotine with 18F-nifene in the thalamus is shown in Figure 5C which shows the displacement of most of the 18F-nifene from the thalamus. Nicotine had little effect in the cerebellum. The nicotine-induced in vivo off-rate measured for 18F-nifene was 0.06 min⁻¹ (Figure 5D).

Occupancy of α4β2 nAChR by nicotine was measured by dose escalation competition experiments of nicotine with 18F-nifene. A change in thalamus binding at baseline was measured at different nicotine doses of injected nicotine. The displacement of 18F-nifene was found with the pre-nicotine challenges. With each dose increase of nicotine, a steady increase in binding occupancy was found. The results are summarized in Table 3. Eighty percent binding occupancy was seen with just 0.02 mg/kg of nicotine while 94% binding occupancy was found with 0.5 mg/kg. Figure 6 presents a steady decrease of 18F-nifene with the competition of nicotine at different doses.

### Discussion

Our primary goal was to evaluate 18F-nifene binding to the α4β2 receptors in thalamic and extrathalamic brain regions of rodents using microPET imaging. 18F-Nifene, an agonist, was developed with fast binding kinetics and a shorter scan time in order to image the α4β2 nicotinic receptors. This is useful in the assessment of nicotinic receptors in neurological diseases. MicroPET studies in rats validated the faster binding profile of 18F-nifene thus providing shorter scan times. Maximum binding was found in the thalamus, while moderate binding is seen in the cortex, and minimal binding in the cerebellum. Time-activity curves for the thalamus, cortex, and cerebellum show that 18F-nifene peaks early into the scan, and nonspecific binding in the cerebellum cleared rapidly. Thalamus to cerebellum ratios were > 3.0 and cortex to cerebellum were approximately 2. Thus, 18F-nifene allows shorter duration PET studies for quantitative measures of α4β2 receptors compared to 2-18F-FA-85380 which has been shown to require 5 h to reach steady state in rodents [17].

No lipophilic metabolites of 18F-nifene were detected in plasma extracts, and a significant amount of 18F-nifene parent remained in the blood after 90 min of the PET study. The absence of lipophilic metabolites was also confirmed using brain extracts of rats injected with 18F-nifene. Only 18F-nifene was detected in the brain extracts.

The binding of 18F-nifene to α4β2 receptors of the rodent brain in microPET studies gave results consistent
with the receptor distribution and was comparable with the autoradiographic slices done in vitro [3]. Test-retest results of binding potentials, summarized in Table 1, remained consistent between scans thus confirming reproducibility of 18F-nifene with <5% standard deviation, suggesting 18F-nifene to be suitable for PET studies. Ex vivo images, both microPET and autoradiographic, confirmed binding of 18F-nifene to thalamic and extrathalamic regions seen in the in vivo microPET study.

Nicotine, because of its high affinity to α4β2 receptors, exhibited competition with 18F-nifene. Previous in vitro studies using 10 nM of nicotine displaced 60-65% in the thalamus region and 300 μM of nicotine, 95% elimination is seen in the thalamus [2]. As expected, displacement of 18F-nifene binding was seen in the post-nicotine challenge similar to that reported for 2-[18F]F-A-85380 [17]. Figure 6 clearly shows a drop in binding at the time of nicotine injection (30 min into the scan), displacing at least > 80% of 18F-nifene binding. The ability for nicotine to compete with 18F-nifene can be used to detect changes in receptor occupancy suggesting PET to be a valuable tool in assessing tobacco-related dependence [13].

![Image](image.png)

**Figure 5** In vivo displacement of 18F-nifene by nicotine. In vivo rat microPET brain slices of 18F-nifene before (A) and after (B) nicotine challenge. (C) Time-activity curve of 18F-nifene specific binding (thalamus-cerebellum) with nicotine (0.3 mg/kg) administered at 30 min pi, displacing 18F-nifene binding in the thalamus (inset shows dissociation rate, koff of 18F-nifene was 0.06 min⁻¹).

### Table 3 Nicotine dose effects on 18F-nifene binding

| Nicotine, mg/kg | % Injected dose/cc thalamus | Nicotine occupancy |
|----------------|-----------------------------|-------------------|
| 0              | 0.489                       | 0%                |
| 0.02           | 0.092                       | 81%               |
| 0.10           | 0.037                       | 92%               |
| 0.25           | 0.031                       | 94%               |
| 0.50           | 0.005                       | 99%               |

Average of two measurements for each dose; receptor occupancy was calculated on the basis of percent injected dose per cubic centimeter of 18F-nifene in the thalamus (ThalCont - ThalNic/ThalCont × 100).
levels of nicotine, demonstrated a steady decrease in 
\(^{18}\text{F}\)-nifene occupancy with respect to nicotine. At low doses of nicotine, 0.02 mg/kg, > 40% of receptors were occupied while at high doses (0.5 mg/kg) > 80% receptors were occupied with nicotine (Table 3). While the cerebellum was used as a reference region, some issues have risen questioning the validity of the cerebellum as a reference region. With the presence of nicotinic receptors in the rat cerebellum [17-19], measurement of binding potential can be complex. Studies using 2-[\(^{18}\text{F}\)]F-A-85380 in rodents have reported nicotine displaceable component in the cerebellum [17], suggesting a need for arterial input function for accurate quantification.

Aside from the cerebellum, efforts have been underway to identify other regions of the brain, such as the corpus callosum and pons as reference regions [20]. Efforts are underway in our rodent \(^{18}\text{F}\)-nifene studies to identify other reference regions in the brain, other than the cerebellum. Future work in the rodent model will incorporate arterial blood sampling for more accurate quantification.

Conclusions

\(^{18}\text{F}\)-nifene binds to the \(\alpha_4\beta_2\) receptors in thalamic and extrathalamic regions in rat microPET studies. With its faster binding kinetics, short scan time, and reversible binding, \(^{18}\text{F}\)-nifene is an agonist radiotracer with potential for studying this receptor system in various rodent models.

Acknowledgements

This research was supported by the National Institutes of Health (NIH), U.S. Department of Health and Human Services, grant no. R01AG029479. We would like to thank Robert Coleman for the technical assistance.

Authors’ contributions

MicroPET imaging studies, autoradiographic studies and analysis were carried out by RK and PP, synthesis and metabolite analysis were carried out by SKP and MLP, brain metabolism studies were carried out by BE and JM, microPET data analysis was carried out by CC. The study and all data acquired was coordinated and reviewed by JM. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 17 March 2011 Accepted: 20 June 2011
Published: 20 June 2011

References

1. Horti AG, Gao Y, Kuwabara H, Dannals RF: Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci 2010, 86:575-584.
2. Pichika R, Easwaramoorthy B, Collins D, Christian BT, Shi B, Narayanan TK, Potkin SG, Mukherjee J: Nicotinic \(\alpha_4\beta_2\) receptor imaging agents. Part II. Synthesis and biological evaluation of 2-\([^{18}\text{F}]\)fluoro-3-\([(S)-3-pyrrolinyl]methoxy\)pyridine (\(^{18}\text{F}\)-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol 2006, 33:294-304.
3. Easwaramoorthy B, Pichika R, Collins D, Potkin SG, Leslie FM, Mukherjee J: Effect of acetylcholinesterase inhibitors on the binding of nicotinic \(\alpha_4\beta_2\) receptor PET radiotracer, \(^{18}\text{F}\)-nifene: a measure of acetylcholine competition. Synapse 2007, 61:29-36.
4. Chefer SI, London ED, Korn AE, Pavlova DA, Kurian V, Kimes AS, Horti AG, Mukhin AG: Graphical analysis of 2-\([^{18}\text{F}]\)FA binding to nicotinic acetylcholine receptors in rhesus monkey brain. Synopsys 2003, 48:25-34.
5. Brody AL, Mandelkern MA, London ED, Olmstead RE, Farah J, Scheibal D, Jou J, Allen V, Tioungson E, Chefer SI, Korn AE, Mukhin AG: Cigarette smoking saturates brain \(\alpha_4\beta_2\) nicotinic acetylcholine receptors. Arch Gen Psychiatry 2006, 63:907-915.
6. Ding YS, Volkow ND, Logan J, Garza V, Pappas N, King P, Fowler JS: Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette. Synapse 2000, 35:234-237.
7. Valette H, Bottlaender M, Dolle F, Coulon C, Ottaviani M, Syrota A: Long-lasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J Neurochem 2003, 84:105-111.
8. Schwartz RD, Kellar KJ: Nicotinic cholinergic receptor binding sites in brain: regulation in vivo. Science 1983, 220:214-216.
9. Marks MJ, Burch JB, Collins AC. Effects of chronic nicotine infusion on
tolerance development and nicotine receptors. J Pharmacol Exp Ther
1983, 226:817-825.
10. Perry DC, Davila-Garcia MI, Stokmeier CA, Kellar KJ. Increased nicotinic
receptor in brains from smokers: membrane binding and
autoradiographic studies. J Pharmacol Exp Ther 1999, 289:1545-1552.
11. Stoleran IP, Jarvis MJ. The scientific case that nicotine is addictive.
Psychopharmacology 1995, 117:2-10.
12. Staley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E,
Dubin JA, Estok K, Brenner E, Baldwin R, Tamagnan GD, Seibyl JP, Jatlow P,
Picciotto MR, London ED, O'Malley S, van Dyck CH. Human tobacco
smokers in early abstinence have higher levels of beta2* nicotinic
acetylcholine receptors than nonsmokers. J Neurosci 2006, 26:8707-8714.
13. Mukhin AG, Kimes AS, Chefer SI, Matrochik JA, Contoreggi CS, Horti AG,
Vaupel DB, Pavlova O, Stein EA. Greater nicotinic acetylcholine receptor
density in smokers than in nonsmokers: a PET study with 2-18F-FA-
85380. J Nucl Med 2008, 49:1628-1635.
14. Sharma A, Brody AL. In vivo brain imaging of human exposure to
nicotine and tobacco. Handb Exp Pharmacol 2009, 192:145-171.
15. McClernon FJ. Neuroimaging of nicotine dependence: key findings and
application to the study of smoking-mental illness comorbidity. J Dual
Disagr 2009, 5:168-178.
16. Constantinescu C, Mukherjee J. Performance evaluation of an Inveon PET
preclinical scanner. Phys Med Biol 2009, 54:2885-2899.
17. Vaupel DB, Stein EA, Mukhin AG. Quantification of alpha2 nicotinic
receptors in the rat brain with microPET and 2-18F-F-A-85380.
Neuroimage 2007, 34:1352-1362.
18. Clarke PBS, Schwartz RD, Paul SM, Pert CB, Pert A. Nicotinic binding in rat
brain: autoradiographic comparison of [1]Hacetylcholine, [1]Hnicotine,
and [125-I]-a-bungarotoxin. J Neuroscience 1985, 5:1307-1315.
19. Flores CM, Rogers SW, Pabreza LA, Wolfe BB, Kellar KJ. A subtype of
nicotinic cholinergic receptor in rat brain in composed of 4 and 2
subunits and is up-regulated by chronic nicotine treatment. J
Pharmacology Exp Ther 1992, 41:31-37.
20. Le Foll B, Cherfi SI, Kimes AS, Shumway D, Goldberg SR, Stein EA,
Mukhin AG. Validation of an extracerebral reference region approach for
the quantification of brain nicotinic acetylcholine receptors in squirrel
monkeys with PET and 2-18F-fluoro-A-85380. J Nucl Med 2007,
48:1492-1500.

doi:10.1186/2191-219X-1-6
Cite this article as: Kant et al: Evaluation of 18F-nifene binding to alpha4beta2 nicotinic receptors in the rat brain using microPET imaging. EJNMMI Research 2011 1:6.